Robert W. Baird Reiterates Neutral Rating for Regeneron Pharmaceuticals Inc. (REGN)
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “neutral” rating reissued by equities researchers at Robert W. Baird in a research note issued to investors on Tuesday. They currently have a $448.00 target price on the biopharmaceutical company’s stock. Robert W. Baird’s price target points to a potential upside of 14.11% from the company’s current price.
REGN has been the subject of a number of other research reports. Leerink Swann set a $511.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, August 6th. RBC Capital Markets restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, August 6th. Cowen and Company restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, June 6th. Piper Jaffray Cos. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, June 6th. Finally, Canaccord Genuity restated a “hold” rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $480.09.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 392.60 on Tuesday. Regeneron Pharmaceuticals has a 1-year low of $329.09 and a 1-year high of $592.59. The firm has a market cap of $41.08 billion, a PE ratio of 61.25 and a beta of 1.31. The company has a 50-day moving average of $403.07 and a 200-day moving average of $391.73.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.65 by $0.17. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.24 billion. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The company’s revenue was up 21.4% on a year-over-year basis. During the same period last year, the business posted $2.89 EPS. Analysts predict that Regeneron Pharmaceuticals will post $11.00 earnings per share for the current fiscal year.
In other news, Director Joseph L. Goldstein sold 2,125 shares of the business’s stock in a transaction on Friday, July 29th. The stock was sold at an average price of $425.00, for a total value of $903,125.00. Following the sale, the director now owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.40% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of the company. IFP Advisors Inc increased its stake in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares in the last quarter. Advisory Services Network LLC increased its stake in Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares in the last quarter. Fuller & Thaler Asset Management Inc. purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $140,000. Brave Asset Management Inc purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $157,000. Finally, Bessemer Group Inc. increased its stake in Regeneron Pharmaceuticals by 45.4% in the first quarter. Bessemer Group Inc. now owns 548 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 171 shares in the last quarter. 68.16% of the stock is currently owned by institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.